TAEST1901 / Guangzhou Xiangxue Pharma - LARVOL DELTA

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (clinicaltrials.gov) - P1/2 | N=600 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

IO biomarker • New P1/2 trial • Oncology • Solid Tumor

Xiangxue Pharmaceutical (300147.SZ): The company’s TAEST16001 injection R&D project is advancing Phase II clinical research [Google translation] (Sina Corp) - "On June 27, 2024, Xiangxue Pharmaceutical stated on the interactive platform that the company's main research direction in the field of cutting-edge biotechnology and pharmaceutical research and development is T cell immunotherapy technology, and its main products include TAEST16001, TAEST1901, etc. The TAEST16001 injection research and development project is mainly used to treat synovial sarcoma. It is currently in the clinical trial stage of new drug registration, and the Phase II clinical research is being carried out in an orderly manner; the TAEST1901 injection research and development project is mainly used to treat primary liver cancer, and other preparations for the launch of Phase I clinical research are being carried out."

Trial status • Liver Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Synovial Sarcoma